Cutaneous reactions to adalimumab administration

Patients receiving antitumour necrosis factor-alpha treatment may develop cutaneous reactions. This human monoclonal antibody is used in the treatment of chronic inflammatory diseases, including arthritis and inflammatory bowel disease. A variety of side effects have been documented ranging from inf...

Full description

Saved in:
Bibliographic Details
Published in:Irish medical journal 2011-04, Vol.104 (4), p.122-123
Main Authors: Downes, M R, Prendiville, S, Kiely, C, Lenane, P, Mulligan, N
Format: Article
Language:English
Subjects:
Adalimumab
Adult
Anti-Inflammatory Agents - adverse effects
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents - adverse effects
Arthritis - drug therapy
Drug Eruptions - etiology
Drug Eruptions - pathology
Humans
Male
Middle Aged
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients receiving antitumour necrosis factor-alpha treatment may develop cutaneous reactions. This human monoclonal antibody is used in the treatment of chronic inflammatory diseases, including arthritis and inflammatory bowel disease. A variety of side effects have been documented ranging from infection and vasculitis through to systemic lupus erythematosus and psoriasis. We report on two arthritic patients treated with adalimumab (Humira, Abbot Laboratories, IL, USA) who developed new onset rashes that resolved with discontinuation of therapy. The frequency of these cutaneous reactions has not been fully established and may benefit from a centralised registry.
ISSN:0332-3102